JPMorgan Starts Dyne Therapeutics (DYN) at Overweight
- Wall Street ends down as data spooks investors awaiting Fed report
- Roblox (RBLX) Lower as DAUs Fall Sequentially
- DraftKings (DKNG) Plunges as Hindenburg's Report Indicates Betting Company's Links to Black Market Operations
- Oracle (ORCL) Tops Q4 EPS by 23c
- U.S. retail sales take step back as spending pivots to services, trend remains strong
JPMorgan initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Overweight rating and a price target of $27.00.
Shares of Dyne Therapeutics closed at $18.64 yesterday.
You May Also Be Interested In
- UPDATE: DA Davidson Starts SPAC Forest Road Acquisition (FRX) at Buy Into Pending Merger with Beachbody
- Jefferies Starts dentalcorp Holdings Ltd (DNTL:CN) at Buy
- Oppenheimer Starts Saratoga Investment (SAR) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!